Ghana
Tuberculosis profile
| High HIV burden |
Population  2013 26 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.69–2.1) 4.4 (2.7–8)
Mortality (HIV+TB only) 0.52 (0.35–0.72) 2 (1.4–2.8)
Prevalence  (includes HIV+TB) 18 (7.9–33) 71 (30–129)
Incidence  (includes HIV+TB) 17 (16–19) 66 (63–74)
Incidence (HIV+TB only) 3.6 (3.4–4) 14 (13–16)
Case detection, all forms (%) 88 (78–93)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
250 (13–700) 200 (1–390)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 7 301   416
Pulmonary, clinically diagnosed 5 979    
Extrapulmonary 1 347    
       
Total new and relapse 15 043    
Previously treated, excluding relapses 563    
Total cases notified 15 606    
Among 15 043 new and relapse cases:
783 (5%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 690 (70%) 690
Laboratory-confirmed RR-/MDR-TB cases     65
Patients started on MDR-TB treatment     26
TB/HIV 2013 Number (%)
TB patients with known HIV status 11 387 (73)
HIV-positive TB patients 2 737 (24)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 780 (65)
HIV-positive TB patients on antiretroviral therapy (ART) 1 009 (37)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 84
Previously treated cases, excluding relapse, registered in 2012 72
HIV-positive TB cases, all types, registered in 2012 73
RR-/MDR-TB cases started on second-line treatment in 2011 50
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 37
% Funded domestically 37%
% Funded internationally 24%
% Unfunded 40%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-29 Data: www.who.int/tb/data